Drug Injury Watch: Multiple Sclerosis (MS) Medication Gilenya: Timeline Of Actions Taken In US, Canada, And Europe

(Posted by Tom Lamb at www.DrugInjuryWatch.com on; August 27, 2012

Increasing Safety Concerns About Novartis Drug Gilenya Are Primarily Cardiovascular Side Effects And Unexplained Death

SUMMARY: Gilenya (fingolimod) was approved by the FDA in September 2010, and its safety is currently under review by the FDA, Health Canada, and the European Medicines Agency (EMA) following reports of cardiovascular side effects and patient deaths occurring immediately after starting the drug.

In August 2012 Novartis, the drug company responsible for this multiple sclerosis (MS) medication, sent a so-called "Dear Doctor" letter to healthcare professionals in Canada alerting them to a label change for Gilenya that included stronger warnings about these adverse reactions.

[Read this article in full at original source]

Earlier articles by Tom Lamb on the Drug Injury Watch blog:

- Increasing Number Of Pradaxa Lawsuits Against Boehringer Are Consolidated In Federal Court MDL
- Levaquin and Avelox Linked To Increased Risk Of Liver Injury In Older Patients According To New Canadian Study
- New 2012 Medical Study Shows NuvaRing Doubles The Risk Of Stroke And Heart Attack, And The Degree Of Risk Increases With Age
- Bayer Settlements: Gianvi / Ocella / Yasmin / YAZ: July 2012 Update On Drug Injury Lawsuits Filed To Date
- Merck's NuvaRing Increases The Relative Risk For Blood-Clot Side Effects Says Medical Expert After Weighing Competing Studies

---

Attorney Tom Lamb represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.
http://www.DrugInjuryWatch.com